Ariad Pharmaceuticals (NASDAQ: ARIA) recently received a number of ratings updates from brokerages and research firms:

  • 10/12/2016 – Ariad Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $20.00 price target on the stock.
  • 10/4/2016 – Ariad Pharmaceuticals is now covered by analysts at SunTrust Banks Inc.. They set a “buy” rating on the stock.
  • 9/28/2016 – Ariad Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $16.00 price target on the stock. According to Zacks, “ARIAD’s cancer treatment, Iclusig, is performing well – sales should be driven by field team expansion, label expansion, increasing clinical experience and patient retention programs. ARIAD finished filing a rolling NDA for its most advanced pipeline candidate, brigatinib in Sep and could well become a two product commercial company in 2017. Longer-term growth could be driven by AP32788 and new opportunities including immuno-oncology. We are positive on the Incyte deal which will allow the company to focus on the U.S. market. It also provides the company with a non-dilutive source of funds. However, we remain concerned about ARIAD’s dependence on a single product, Iclusig, for near-term growth. Additionally, concerns regarding tougher label warnings could remain an overhang. Competition in the oncology market is also high.”
  • 9/26/2016 – Ariad Pharmaceuticals is now covered by analysts at Leerink Swann. They set an “outperform” rating on the stock.

Shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) traded down 3.29% on Friday, reaching $12.64. The company had a trading volume of 2,015,658 shares. The firm’s market capitalization is $2.44 billion. The firm has a 50-day moving average price of $12.15 and a 200 day moving average price of $9.00. Ariad Pharmaceuticals Inc. has a 1-year low of $4.37 and a 1-year high of $14.34.

Ariad Pharmaceuticals (NASDAQ:ARIA) last announced its quarterly earnings data on Thursday, July 28th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.70. The business earned $65.30 million during the quarter, compared to analysts’ expectations of $60.64 million. During the same period in the prior year, the firm posted ($0.28) EPS. Ariad Pharmaceuticals’s revenue for the quarter was up 133.0% compared to the same quarter last year. Equities research analysts predict that Ariad Pharmaceuticals Inc. will post ($0.09) earnings per share for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

In other Ariad Pharmaceuticals news, VP Daniel M. Bollag sold 47,384 shares of Ariad Pharmaceuticals stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $13.46, for a total value of $637,788.64. Following the sale, the vice president now owns 129,404 shares of the company’s stock, valued at approximately $1,741,777.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Timothy P. Clackson sold 8,750 shares of Ariad Pharmaceuticals stock in a transaction that occurred on Wednesday, September 28th. The shares were sold at an average price of $13.98, for a total value of $122,325.00. Following the completion of the sale, the insider now directly owns 226,272 shares in the company, valued at approximately $3,163,282.56. The disclosure for this sale can be found here. 8.20% of the stock is owned by company insiders.

ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

5 Day Chart for NASDAQ:ARIA

Receive News & Ratings for Ariad Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ariad Pharmaceuticals Inc and related companies with's FREE daily email newsletter.